Pavel Balazki
Field of research
|
Curriculum vitae
Since 03/2016: Doctoral student Clinical Pharmacy, Saarland University, Saarbrücken
10/2014 – 12/2017: Doctoral student Systems Pharmacology, Bayer AG
10/2009 – 10/2014: Bioinformatics studies, Goethe-Universität, Frankfurt am Main
06/2008: Abitur, Hohe Landesschule Hanau
Manuscripts
Balazki P, Schaller S, Eissing T, Lehr T. A physiologically-based quantitative systems pharmacology model of the incretin hormones GLP-1 and GIP and the DPP4 inhibitor sitagliptin. CPT Pharmacometrics Syst Pharmacol 2020;9(6):353-362. Balazki P, Schaller S, Eissing T, Lehr T. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of the SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol 2018;7(12):788-797. Balazki P, Lindauer K, Einloft J, Ackermann J, Koch I. MONALISA for stochastic simulations of Petri net models of biochemical systems. BMC Bioinformatics 2015;16:215. |
Posters
Balazki P, Schaller S, Eissing T, Lehr T. A physiologically-based quantitative systems pharmacology model of the incretin hormones GLP-1 and GIP. 27th Population Approach Group Europe (PAGE) meeting, 2018, Montreux, Switzerland. Balazki P, Eissing T, Lehr T. Physiologically-based pharmacokinetics/pharmakodynamics (PBPK/PD) systems pharmacology model of glucose homeostasis in human. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany. Balazki P, Woerle V, Schaller S, Eissing T, Lehr T. Physiologically-based pharmacokinetics/pharmacodynamics model of dapagliflozin, an oral SGLT2 inhibitor. 26th Population Approach Group Europe (PAGE) meeting, 2017, Montreux, Switzerland. |